Balancing the decision of cell proliferation and cell fate

Cell Cycle

Volumn 8, Issue 4, 2009, Pages 532-535

  Hallstrom, Timothy C ^a   Nevins, Joseph R ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Apoptosis; E2F1; Microarray; PI3K; Proliferation

Indexed keywords

PROTEIN P53; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR E2F1;

APOPTOSIS; CELL FATE; CELL PROLIFERATION; DNA REPLICATION; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMAN; MITOSIS; NONHUMAN; PROTEIN FUNCTION; REGULATORY MECHANISM; RETINOBLASTOMA; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 61449249141     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.4.7609     Document Type: Review

References (60)

1. van den Heuvel S, Dyson N. Conserved functions of the pRB and E2F families. Nat Rev Mol Cell Biol 2008; 9:713-24.
2. Iaquinta PJ, Lees JA. Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol 2007; 19:649-57.
3. DeGregori J, Johnson DG. Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr Mol Med 2006; 6:739-48.
4. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993; 365:349-52.
5. Leone G, DeGregori J, Yan Z, Jakoi L, Ishida S, Williams RS, et al. E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev 1998; 12:2120-30.
6. Kong L-J, Chang JT, Bild AH, Nevins JR. Compensation and specificity of function within the E2F family. Oncogene 2007; 26:321-7.
7. Leone G, Sears R, Huang E, Rempel R, Nuckolls F, Park C-H, et al. Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell 2001; 8:105-13.
8. Slansky JE, Li Y, Kaelin WG, Farnham PJ. A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Mol Cell Biol 1993; 13:1610-8.
9. Johnson DG, Ohtani K, Nevins JR. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 1994; 8:1514-25.
10. Luo RX, Postigo AA, Dean DC. Rb interacts with histone deacetylase to repress transcription. Cell 1998; 92:463-73.
11. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. Cell 1991; 65:1053-61.
12. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13:1501-12.
13. O'Shea CC. DNA tumor viruses - the spies who lyse us. Curr Opin Genet Dev 2005; 15:18-26.
14. Dick FA, Dyson N. pRB contains an E2F1-specific binding domain that allows E2F1-induced apoptosis to be regulated separately from other E2F activities. Mol Cell 2003; 12:639-49.
15. Wu X, Levine AJ. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 1994; 91:3602-6.
16. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci USA 1997; 94:7245-50.
17. Hallstrom TC, Nevins JR. Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci USA 2003; 100:10848-53.
18. Denchi EL, Helin K. E2F1 is crucial for E2F-dependent apoptosis. EMBO Rep 2005; 6:661-8.
19. Muller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E, et al. E2Fs regulate the expression of genes involved in differentiation, development, proliferation and apoptosis. Genes Dev 2001; 15:267-85.
20. Ishida S, Huang E, Zuzan H, Spang R, Leone G, West M, et al. Role for E2F in the control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol 2001; 21:4684-99.
21. Polager S, Kalma Y, Berkovich E, Ginsberg D. E2Fs upregulate expression of genes involved in DNA replication, DNA repair and mitosis. Oncogene 2002; 21:437-46.
22. Ma Y, Croxton R, Moorer RL, Cress WD. Identification of novel E2F1-regulated genes by microarray. Arch Biochem Biophys 2002; 399:212-24.
23. Zhu JW, DeRyckere D, Li FX, Wan YY, DeGregori J. A role for E2F1 in the induction of ARF, p53 and apoptosis during thymic negative selection. Cell Growth Differ 1999; 10:829-38.
24. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, et al. p14ARF links the tumour suppressors RB and p53. Nature 1998; 395:124-5.
25. Irwin M, Martin MC, Phillips AC, Seelan RS, Smith DI, Liu W, et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 2000; 407:645-8.
26. Lissy NA, Davis PK, Irwin M, Kaelin WG, Dowdy SF. A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature 2000; 407:642-4.
27. Stiewe T, Putzer BM. Role of the p53 homologue p73 in E2F1-induced apoptosis. Nat Genet 2000; 26:464-9.
28. Nahle Z, Polakoff J, Davuluri RV, McCurrach ME, Jacobson MD, Narita M, et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol 2002; 4:859-64.
29. Tracy K, Dibling B, Spike B, Knabb J, Schumacker P, Macleod K. BNIP3 is an RB/E2F target gene required for hypoxia-induced autophagy. Mol Cell Biol 2007; 27:6229-42.
30. Rodriguez J, Glozak M, Ma Y, Cress W. Bok, Bcl-2-related ovarian killer, is cell cycle-regulated and sensitizes to stress-induced apoptosis. J Biol Chem 2006; 281:22729-35.
31. Biswas SC, Liu DX, Greene LA. Bim is a direct target of a neuronal E2F-dependent apoptotic pathway. J Neurosci 2005; 25:8349-58.
32. Hershko T, Ginsberg D. Upregulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem 2004; 279:8627-34.
33. Croxton R, Ma Y, Song L, Haura EB, Cress WD. Direct repression of the Mcl-1 promoter by E2F1. Oncogene 2002; 21:1359-69.
34. Chaussepied M, Ginsberg D. Transcriptional regulation of AKT activation by E2F. Mol Cell 2004; 16:831-7.
35. Rogoff HA, Pickering MT, Debatis ME, Jones S, Kowalik TF. E2F1 induces phosphorylation of p53 that is coincident with p53 accumulation and apoptosis. Mol Cell Biol 2002; 22:5308-18.
36. Rogoff HA, Pickering MT, Frame FM, Debatis ME, Sanchez Y, Jones S, et al. Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbs1/Chk2. Mol Cell Biol 2004; 24:2968-77.
37. Shan B, Lee W-H. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol Cell Biol 1994; 14:8166-73.
38. Moon N, Di Stefano L, Dyson N. A gradient of epidermal growth factor receptor signaling determines the sensitivity of rbf1 mutant cells to E2F-dependent apoptosis. Mol Cell Biol 2006; 26:7601-15.
39. Kauffmann-Zeh A, Rodriquez-Viciana P, Elrich E, Gilbert C, Coffer P, Downward J, et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997; 385:544-8.
40. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91:231-41.
41. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin 3 induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278:687-9.
42. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase 9 by phosphorylation. Science 1998; 282:1318-21.
43. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001; 98:11598-603.
44. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung M-C. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001; 3:973-82.
45. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K, et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 2002; 277:21843-50.
46. Chang JT, Nevins JR. GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 2006; 22:2926-33.
47. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, et al. AMP activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005; 18:283-92.
48. Bowles J, Knight D, Smith C, Wilhelm D, Richman J, Mamiya S, et al. Retinoid signaling determines germ cell fate in mice. Science 2006; 312:596-600.
49. Cheng LE, Chan FK, Cado D, Winoto A. Functional redundancy of the Nur77 and Nor-1 orphan steroid receptors in T-cell apoptosis. EMBO J 1997; 16:1865-75.
50. Mullican S, Zhang S, Konopleva M, Ruvolo V, Andreeff M, Milbrandt J, et al. Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med 2007; 13:730-5.
51. Pina C, May G, Soneji S, Hong D, Enver T. MLLT3 regulates early human erythroid and megakaryocytic cell fate. Cell Stem Cell 2008; 2:264-73.
52. Shimamoto A, Kitao S, Ichikawa K, Suzuki N, Yamabe Y, Imamura O, et al. A unique human gene that spans over 230 kb in the human chromosome 8p11-12 and codes multiple family proteins sharing RNA-binding motifs. Proc Natl Acad Sci USA 1996; 93:10913-7.
53. Hallstrom TC, Nevins JR. Jab1 is a specificity factor for E2F1-induced apoptosis. Genes Dev 2006; 20:613-23.
54. Evan GL, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69:119-28.
55. Black EP, Hallstrom T, Dressman HK, West M, Nevins JR. Distinctions in the specificity of E2F function revealed by gene expression signatures. Proc Natl Acad Sci USA 2005; 102:15948-53.
56. Giangrande PH, Hallstrom TC, Tunyaplin C, Calame K, Nevins JR. Identification of the E box factor TFE3 as a functional partner for the E2F3 transcription factor. Mol Cell Biol 2003; 23:3707-20.
57. Schlisio S, Halperin T, Vidal M, Nevins JR. Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J 2002; 21:5775-86.
58. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439:353-7.
59. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108:1167-74.
60. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29:254-8.